TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
Status:
Completed
Trial end date:
2020-06-12
Target enrollment:
Participant gender:
Summary
Investigators conducted this study to see the effectiveness of Tocilizumab in COVID-19
participants who were in cytokine release syndrome and there was also a control group who
received steroids(RECOVERY TRIAL wasn't published or available at that time) this study was
conducted in the early days of 1st wave of COVID in our country Pakistan so it was need of
the day to develop some national guidelines on the basis of multiple studies' results from
Pakistan.